1. Generics Bulletin
  2. >>Products

Januvia Generics Arrive In India

MSD Defends Its Turf As Sitagliptin Looks To Unseat Teneligliptin, Vildagliptin

 
• By Anju Ghangurde

A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the originator respond with price cuts?

Can Merck Hold Its Ground For Januvia In India? • Source: Shutterstock

Dozens of sitagliptin generic brands are expected to swarm the Indian market in the days to come with Merck & Co., Inc.'s blockbuster diabetes drugs, Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride) losing patent cover this month in the country.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By Dean Rudge

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

How To Make The Most Of Your GGB Awards Entries

 
• By Dave Wallace

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

Denosumab Race Heats Up In Europe With Eight More Nods

 
• By Dave Wallace

Denosumab competition is heating up in Europe, with four more companies this month gaining EMA endorsements for their Prolia and Xgeva biosimilar rivals.